GLP-1 receptor agonists like semaglutide and tirzepatide have revolutionized weight loss and diabetes care
A slower metabolic rate can delay this process, keeping the drug detectable for longer
Step 4 - Ongoing monitoring
Microdosing protocols vary from person to person, but most people start with 0.05mg to 0.25mg per week
The follow up period used to examine outcomes irrespective of ongoing use of the medication (emulating a modified intention-to-treat analysis of a clinical trial), started from the index date, and continued until study end (October 30, 2021), death, or initiation of a GLP1-RA in the DPP4i group, whichever came first (Fig
These formulations are prepared by pharmacists under strict quality standards, though they are not Health Canada-approved branded products